Floor J. Backes, MD, discusses the side effects associated with the combination lenvatinib plus paclitaxel in patients with recurrent endometrial and platinum-resistant epithelial ovarian cancer.
Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses the side effects associated withthe combination lenvatinib (Lenvima) plus paclitaxel in patients with recurrent endometrial and platinum-resistant epithelial ovarian cancer.
The toxicities were typical to that of other chemotherapy agents, says Backes. This includes cytopenia, anemia, leukopenia, and some thrombocytopenia. It was mostly the white and red cells that were affected.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More